how long to stop tirzepatide before pregnancy Taking Tirzepatide: Safe Discontinuation Guide tirzepatide pregnancy safety studies GLP-1

In the key Phase 3 ATTAIN-1 trial published in the New England Journal of Medicine in 2025, once-daily orforglipron 36 mg produced mean body weight reductions of 11.2% at 72 weeks in adults with obesity, with nearly 55% of participants achieving at least 10% weight loss and 36% achieving 15% or more

Novo Nordisk was the pioneer--winning a 2014 FDA-approval for liraglutide (Saxenda) as an obesity treatment, formulated as a once-daily subcutaneous injection

Presentation of BPC-157 may stimulate the growth hormone (GH) receptors, thereby inducing similar GH potential

Nutrient Density: Ensuring every bite counts even when your appetite is low

But some GLP-1 users report taste changes or increased acid reflux with coffee